CN104857040A - New purpose of embelia parviflora wall for preparing medicines for treating liver fibrosis - Google Patents
New purpose of embelia parviflora wall for preparing medicines for treating liver fibrosis Download PDFInfo
- Publication number
- CN104857040A CN104857040A CN201510297286.9A CN201510297286A CN104857040A CN 104857040 A CN104857040 A CN 104857040A CN 201510297286 A CN201510297286 A CN 201510297286A CN 104857040 A CN104857040 A CN 104857040A
- Authority
- CN
- China
- Prior art keywords
- radix seu
- seu caulis
- caulis embeliae
- embeliae parviflorae
- total flavones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a new purpose of embelia parviflora wall, namely a new purpose of the embelia parviflora wall for preparing medicines for treating liver fibrosis, in particular to a new purpose of an embelia parviflora wall extract and general flavone of the embelia parviflora wall for preparing the medicines for treating the liver fibrosis.
Description
Technical field
The present invention relates to the novelty teabag of Radix seu Caulis Embeliae Parviflorae, particularly the novelty teabag of Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones, the novelty teabag namely in preparation treatment hepatic fibrosis medicines.
Background technology
Hepatic fibrosis is hepatic injury sustainable existence, the pathological process caused because extracellular matrix synthesis, degraded and deposition are uneven when tissue occurs to repair reaction, liver inner cell-cell, cell-matrix, substrate-mediator interphase interaction, the complex networks system formed, participates in generation and the development of hepatic fibrosis.Hepatic fibrosis is the important pathological characters of chronic hepatopathy, is also further to the main intermediate link of cirrhosis progress.If cause of disease sustainable existence, hepatic fibrosis increases the weight of gradually, and lobules of liver normal configuration is destroyed, and interval appears in central vein district and portal area, pseudolobuli is formed, and namely develops into liver cirrhosis.Liver cirrhosis not only can cause the complication such as the exhaustion of Chronic Liver cell function and portal hypertension, also can develop into hepatocarcinoma.
The liver tissue inflammation grade occurred in liver fibrosis process and pathological belong to the pathogenesis of the traditional Chinese medical science " blood stasis " from microcosmic syndrome differentiation.
Radix seu Caulis Embeliae Parviflorae (Embelia parviflora Wall) is Myrsinacea flower acid vine platymiscium, also known as Embelia parviflora Wall, Radix seu Caulis Embeliae Parviflorae, sieve that it is strong, for evergreen woody climber, be used as medicine with the rattan of its drying or root, the ground such as the Guangxi that mainly distributes (Longzhou, large new, sky etc., Baise, rivers and ponds), Guangdong, Guizhou, Yunnan.Its nature and flavor are bitter, puckery, flat.Strong doctor thinks that Radix seu Caulis Embeliae Parviflorae has the function of Tong Longlu fire road, tonifying blood and regulating menstruation, nourishing essence and tonifying YANG, strong waist knee joint, it is conventional strong medicine kind, for (anemia), capital plucked instrument (amenorrhea) in strangling, menoxenia, grand white slow-witted (leukorrhagia), send out prosperous (rheumatic ostalgia), lumbago and skelalgia, costalgia of chest, stomachache, chronic enteritis, puerperal abdonimal pain, the blunt crotch of porphin (infertility) etc., genus rheumatism key medicine.Guangxi special product Chinese patent medicine " osmanthus dragon ointment " with this medical material for raw material.
" the trial test research of Radix seu Caulis Embeliae Parviflorae chemical composition " " Colleges Of Traditional Chinese Medicine Of Guangxi's journal " finds, may contain the compositions such as saccharide, glycoside, phenols, tannin, saponin, organic acid, flavonoid, triterpenes, steroid, volatile oil and oils and fats in Radix seu Caulis Embeliae Parviflorae.
Study (" Radix seu Caulis Embeliae Parviflorae different parts volatile oil component GC-MS analyzes " " Agriculture of Anhui science ") according to people such as Lu Senhua, all containing 2-n-pentyl furan, myristic acid, Palmic acid and linoleic acid in Radix seu Caulis Embeliae Parviflorae root, stem, leaf volatile oil, in root, content is up to linoleic acid, and in stem, content is up to Palmic acid.
In the Study on extraction of total saponins " in the Radix seu Caulis Embeliae Parviflorae " " time precious traditional Chinese medical science traditional Chinese medicines ", Liu waited people quietly in the research to Radix seu Caulis Embeliae Parviflorae chemical composition, and be separated and obtain a large amount of saponins compound, its main component is ardisiacrispin B.Saponins compound often has good anti-tumor activity, and ardisiacrispin B is as one of the important component of Chinese medicine Radix Ardisiae Crispae, and to tumor cell MCF-7, NCI-H460 and SF-268 has very strong cytotoxic activity.
" in determined by ultraviolet spectrophotometry Radix seu Caulis Embeliae Parviflorae catechin content " " Agriculture of Anhui science " pipe hypo etc., in the research process to Radix seu Caulis Embeliae Parviflorae chemical composition, are separated and obtain a large amount of catechins.Catechin has the plurality of health care functions such as antibacterial, antiinflammatory, Tumor suppression, antioxidation, defying age, anti-distortion, blood pressure lowering, blood fat reducing, blood sugar lowering, radioprotective.
" in Radix seu Caulis Embeliae Parviflorae total flavone extracting process research " " food industry science and technology " report for total flavone extracting process research in Radix seu Caulis Embeliae Parviflorae, but is only index by total flavones yield.
Do not retrieve the bibliographical information that Radix seu Caulis Embeliae Parviflorae, Radix seu Caulis Embeliae Parviflorae extract or Radix seu Caulis Embeliae Parviflorae total flavones can be used for treating hepatic fibrosis at present.
Summary of the invention
The object of this invention is to provide the novelty teabag of Radix seu Caulis Embeliae Parviflorae in preparation treatment hepatic fibrosis medicines;
Another object of the present invention is to provide the novelty teabag of Radix seu Caulis Embeliae Parviflorae extract in preparation treatment hepatic fibrosis medicines;
Another object of the present invention is to provide the novelty teabag of Radix seu Caulis Embeliae Parviflorae total flavones in preparation treatment hepatic fibrosis medicines;
Another object of the present invention is to provide the preparation method of Radix seu Caulis Embeliae Parviflorae extract;
Another object of the present invention is to provide the preparation method of Radix seu Caulis Embeliae Parviflorae total flavones.
The object of the invention is by following technical scheme realize:
Raw material sources of the present invention:
Radix seu Caulis Embeliae Parviflorae: be Myrsinacea flower acid vine platymiscium Embelia parviflora Wall, also known as Embelia parviflora Wall, Radix seu Caulis Embeliae Parviflorae, sieve that it is strong, for evergreen woody climber, be used as medicine with the rattan of its drying or root, the ground such as the Guangxi that mainly distributes (Longzhou, large new, sky etc., Baise, rivers and ponds), Guangdong, Guizhou, Yunnan.Nature and flavor are bitter, puckery, flat.
Inventor finds in the therapeutic process of research hepatic fibrosis; Myrsinacea plant Radix seu Caulis Embeliae Parviflorae particularly total flavones contained by Radix seu Caulis Embeliae Parviflorae shows and can significantly improve rat liver fibrosis degree; alleviate liver tissues inflammatory cellular infiltration and steatosis degree; show that Radix Angelicae Sinensis total flavones has Anti Fibrosis of Liver; the effect of protection hepatocyte, is improved effect to liver function.
During hepatic fibrosis pathological changes, hepatocyte is damaged death, and ALT, AST etc. of its synthesis secretion are just transferred to blood through liver plasma membrane, and the content in blood is obviously raised; In addition, liver cell destruction is dead, and the albumin causing it to synthesize reduces.Therefore, ALT, AST, albumin serum levels can reflect hepatocyte injury degree.And LN level can reflect the Random early Detection of liver and the active process of liver tissue lesions, to the indication generation of hepatic fibrosis and the early diagnosis of liver cirrhosis, there is important value.During hepar damnification, in liver, Interstitial cell synthesis HA increases, and sinusoidal endothelial cell is impaired, and quantity reduces, and HA is decomposed and reduces, thus serum HA content is increased.Find under study for action; after the hepatic fibrosis rats that CCl4 induces gives Radix seu Caulis Embeliae Parviflorae total flavones, Serum ALT, AST content significantly reduce; albumin content significantly raises; LN, HA significantly reduce; show that Radix Angelicae Sinensis total flavones has Anti Fibrosis of Liver; the effect of protection hepatocyte, is improved effect to liver function.
Certainly, Radix seu Caulis Embeliae Parviflorae total flavones may be a complicated mechanism to the Hepatocyte protection of hepatic fibrosis rats, and concrete mechanism also needs to make further research.Although also not exclusively clear to its concrete mechanism of action at present, Radix seu Caulis Embeliae Parviflorae total flavones has treatment and Hepatocyte protection preferably to hepatic fibrosis rats, points out its fibrosis effect, thus protection damaged liver.
The safety of patent clinical practice of the present invention is higher, a kind of good medicine of can yet be regarded as in the Drug therapy for the treatment of hepatic fibrosis, and it has widened the new method for the treatment of hepatic fibrosis, the untoward reaction simultaneously for occurring when patient solves prior art treatment hepatic fibrosis.
Therefore, applicant provides Radix seu Caulis Embeliae Parviflorae, Radix seu Caulis Embeliae Parviflorae extract, Radix seu Caulis Embeliae Parviflorae total flavones to can be used in treating the novelty teabag of hepatic fibrosis medicines aspect.
The invention also discloses the application of Radix seu Caulis Embeliae Parviflorae extract at preparation treatment hepatic fibrosis medicines, the preparation of described Radix seu Caulis Embeliae Parviflorae extract comprises the following steps:
Radix seu Caulis Embeliae Parviflorae is pulverized, and adding concentration is that the 50-70 DEG C of water-bath of 60-80% ethanol is extracted 2-3 time, and each ethanol consumption is medical material gross weight 8-12 times, and each extraction time is 40-60min, merge extractive liquid, concentrated, filters, concentrated, dry, obtains Radix Angelicae Sinensis rattan extract.
Radix seu Caulis Embeliae Parviflorae total flavones disclosed by the invention is in the application of preparation treatment hepatic fibrosis medicines, and described Radix seu Caulis Embeliae Parviflorae total flavones is prepared by following steps:
Radix seu Caulis Embeliae Parviflorae is pulverized, adding concentration is 50-80% ethanol microwave extraction 2-3 time, each ethanol consumption is medical material gross weight 8-15 times, and each extraction time is 10-20min, merge extractive liquid, concentrated, filter, filtrate is 60-80% ethanol elution by concentration after crossing weak-acid cation-exchange resin absorption, eluent is concentrated, vacuum drying, obtains Radix seu Caulis Embeliae Parviflorae total flavones.
Radix seu Caulis Embeliae Parviflorae total flavones disclosed by the invention is in the application of preparation treatment hepatic fibrosis medicines, and described Radix seu Caulis Embeliae Parviflorae total flavones can also be prepared by following steps:
Radix seu Caulis Embeliae Parviflorae is pulverized, adding concentration is 60% ethanol, and by 780W microwave extraction 2-3 time, each ethanol consumption is medical material gross weight 12 times, each extraction time is 15min, merge extractive liquid, concentrating under reduced pressure, adds diatomite filtration, filtrate crosses ADS17 resin absorption, use 70% ethanol elution, eluent be concentrated, vacuum drying, obtain Radix seu Caulis Embeliae Parviflorae total flavones.
The novelty teabag that Radix seu Caulis Embeliae Parviflorae provided by the invention, Radix seu Caulis Embeliae Parviflorae extract, Radix seu Caulis Embeliae Parviflorae total flavones are used for the treatment of hepatic fibrosis medicines aspect has the following advantages:
1, Radix seu Caulis Embeliae Parviflorae, Radix seu Caulis Embeliae Parviflorae extract, Radix seu Caulis Embeliae Parviflorae total flavones belong to Radix seu Caulis Embeliae Parviflorae from Myrsinacea flower acid vine and obtaining, and safety non-toxic, can long-term taking.
2, experimental result shows, Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones significantly can reduce the ALT of hepatic fibrosis rats, AST (P<0.01 or P<0.05), the albumin (P<0.01 or P<0.05) of remarkable rising hepatic fibrosis rats, the LN of remarkable reduction hepatic fibrosis rats, HA (P<0.01 or P<0.05), can obviously improve rat liver fibrosis degree, alleviate liver tissues inflammatory cellular infiltration and steatosis degree, show that Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones have Anti Fibrosis of Liver, the effect of protection hepatocyte, effect is improved to liver function.Overall experiment effect display, Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones effectively can treat hepatic fibrosis, and therapeutic effect optimum is Radix seu Caulis Embeliae Parviflorae total flavones, and Radix seu Caulis Embeliae Parviflorae extract takes second place, but both all demonstrate significant therapeutic effect.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Except as otherwise noted, the percent of the amount of alcohol in the present invention is percentage by volume, and v/v represents the volume ratio of solution.
Embodiment 1: the preparation of Radix seu Caulis Embeliae Parviflorae extract
Get 10kg Radix seu Caulis Embeliae Parviflorae to pulverize, add concentration be 80% ethanol water bath extract 3 times, each ethanol consumption is respectively 12 times, 10 times, 8 times of medical material gross weight, bath temperature is 70 DEG C, and each extraction time is respectively 60min, 50min, 40min, merge extractive liquid, concentrated, filter, dry, obtain Radix Angelicae Sinensis rattan extract.
Compare product with rutin, surveying Radix seu Caulis Embeliae Parviflorae total flavones yield is 0.35%.
Embodiment 2: the preparation of Radix seu Caulis Embeliae Parviflorae total flavones
Get 10kg Radix seu Caulis Embeliae Parviflorae to pulverize, add the ethanol that concentration is 80%, by 780W microwave extraction 2-3 time, each ethanol consumption is 12 times of medical material gross weight, each extraction time is 15min, merge extractive liquid, concentrating under reduced pressure, adds diatomite filtration, filtrate crosses ADS17 resin absorption, use 70% ethanol elution, eluent be concentrated, vacuum drying, obtain Radix seu Caulis Embeliae Parviflorae total flavones.
Compare product with rutin, surveying Radix seu Caulis Embeliae Parviflorae total flavones yield is 0.49%.
Embodiment 3: the preparation of Radix seu Caulis Embeliae Parviflorae total flavones
Get 10kg Radix seu Caulis Embeliae Parviflorae to pulverize, add the ethanol microwave extraction 3 times that concentration is 60%, each ethanol consumption is respectively 15 times, 10 times, 8 times of medical material gross weight, and each extraction time is respectively 20min, 15min, 10min, merge extractive liquid, concentrated, filter, filtrate crosses ADS17 resin absorption, is the ethanol elution of 80% by concentration, eluent is concentrated, vacuum drying, obtains Radix seu Caulis Embeliae Parviflorae total flavones.
Compare product with rutin, surveying Radix seu Caulis Embeliae Parviflorae total flavones yield is 0.66%.
Embodiment 4: the preparation of Radix seu Caulis Embeliae Parviflorae total flavones
Get 10kg Radix seu Caulis Embeliae Parviflorae to pulverize, add the ethanol microwave extraction 2 times that concentration is 50%, each ethanol consumption is 8 times of medical material gross weight, and each extraction time is 10min, merge extractive liquid, concentrated, filter, filtrate crosses ADS17 resin absorption, is the ethanol elution of 50% by concentration, eluent is concentrated, vacuum drying, obtains Radix seu Caulis Embeliae Parviflorae total flavones.
Compare product with rutin, surveying Radix seu Caulis Embeliae Parviflorae total flavones yield is 0.45%.
Embodiment 5: the preparation of Radix seu Caulis Embeliae Parviflorae extract
Get 10kg Radix seu Caulis Embeliae Parviflorae to pulverize, add concentration be 60% ethanol water bath extract 2 times, each ethanol consumption is 8 times of medical material gross weight, and bath temperature is 50 DEG C, and each extraction time is 40min, merge extractive liquid, concentrated, filters, dry, obtains Radix Angelicae Sinensis rattan extract.
Compare product with rutin, surveying Radix seu Caulis Embeliae Parviflorae total flavones yield is 0.32%.
Effect experiment: Anti Fibrosis of Liver
1. experiment material
1.1 animal
Wistar rat, female, SPF level, body weight 180 ~ 220g, 60, purchased from Guangxi Medical University's Experimental Animal Center.
1.2 reagent
Carbon tetrachloride (Haizhu District of Guangzhou city chemical reagent factory, RA); Olive oil (Chemical Reagent Co., Ltd., Sinopharm Group); Serum glutamic pyruvic transminase, glutamic oxaloacetic transaminase, GOT detectable, albumin detection reagent (stepping auspicious medical treatment); Hyaluronic acid detectable, laminin，LN (LN) put inspection-free test agent (Shanghai INM).
1.3 medicine
Malotilate (Ya Baoxin, Shanxi Ya Bao Pharmaceutical group), embodiment 1, embodiment 2, embodiment 3 (embodiment 1-3 be before use that 0.2% sodium carboxymethyl cellulose be mixed with concentration be 15mg/ml by mass concentration).
2. experimental technique
2.1 modelings, administration: rat is divided into 5 groups at random by body weight, often organize 12, be respectively blank group, model group, embodiment 1 group, embodiment 2 groups, embodiment 3 groups, Malotilate sheet group (positive drug).Except blank group, other group adopts 40%CCL4 olive oil solution, 2ml/kg body weight lumbar injection, 2 times weekly, continues 8 weeks.Embodiment group and the administration after the 4th modeling of positive drug group, embodiment 1-3 group dosage is 150mg/kg (to prepare the dry powder of gained), Ma Luo is 60mg/kg for lipid dose, 1 times/day, blank group gives isometric(al) distilled water with model group, gavage volume is 1ml/100g body weight, successive administration 6 weeks.
2.2 animal process and Indexs measure: after last administration, anesthetized rat is taken a blood sample from ventral aorta, centrifuging and taking Virus monitory liver function and fibrosis indices in hepatic; Get liver after blood sampling to weigh, calculate liver coefficient, and get lobus dexter hepatic tissue with 10% neutral formalin solution fix, through HE dyeing observation degree of hepatic fibrosis.
Laboratory animal degree of hepatic fibrosis grade scale carries out classification, is divided into 0 ~ 6 grade.0 grade: lobules of liver structural integrity, without cell infiltration, without fibrosis hypertrophy; 1 grade: a small amount of collagen fiber stretch out from portal area or central vein district; 2 grades: collagen fiber stretch out obviously around portal area or central vein, but do not hold whole lobules of liver; 3 grades: collagen fiber extend obviously, are interconnected, hold whole lobules of liver; 4 grades: collagen fiber hold segmentation lobules of liver, thus normal hepatocytes leaflet structure destroys, and pseudolobuli is formed, but is formed as main with large oval pseudolobuli; 5 grades: lobules of liver structure is destroyed completely, pseudolobuli is formed, and large oval pseudolobuli and small circular pseudolobuli respectively account for 50%; 6 grades: in liver, be covered with circular pseudolobuli, between pseudolobuli, there are the collagen fiber of thick hypertrophy.
3. statistical procedures
Ranked data are pressed in liver cirrhosis pathology classification in histological examination, and the comparison in difference between each group adopts rank test; Biochemical detection by quantitative result represents with mean ± standard deviation by measurement data, and the variation analysis between each group adopts t inspection.The statistical software used thinks that difference has significance for SPSS13.0, P<0.05.
4. experimental result
4.1 animal ordinary circumstances
After rat CCl4 injects there is Agitation in short-term, and showing as movable to increase, run, then for suppressing symptom, show as movablely to reduce, group's contracting, whole body is by the sparse tarnish of hair, and from symptom degree, medicine group all has and alleviates, and has no ascites generation.Each treated animal liver is heavy/and body weight ratio is in table 1.
Table 1. each treated animal liver weight/body weight ratio
Note: compare with blank group, * * P < 0.01; Compare with model group, #P < 0.05, ##P < 0.01.
Table 1 result shows, model group liver weight/body weight ratio significantly raises (P<0.01), positive drug group, embodiment 1-3 group liver weight/body weight ratio all have reduction, and significant difference (P<0.01 or P<0.05).Show that Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones all obviously can improve the general disease of hepatic fibrosis rats.
4.2 Liver function grade, the results are shown in Table 2
Table 2. is group serum liver Function detection index respectively
Note: compare with blank group, * * P<0.01; Compare with model group, #P<0.05, ##P<0.01.
Table 2 result shows, compare with blank group, model group rats serum AST, ALT content significantly raise (P<0.01 or P<0.05), and albumin content significantly reduces (P<0.01); Compare with model group, positive drug group, enforcement 1-3 group AST, ALT content all significantly reduce (P<0.01 or P<0.05), and albumin content all significantly raises (P<0.01 or P<0.05).Show that Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones can effectively improve the liver function of hepatic fibrosis rats.
4.3 serum hepatic fibrosis detect, and the results are shown in Table 3
Table 3. is group serum hepatic fibrosis Testing index respectively
Note: compare with blank group, * * P<0.01; Compare with model group, #P<0.05, ##P<0.01.
Table 3 result shows, and compare with blank group, model group rats serum HA, LN content significantly raises (P<0.01); Compare with model group, positive drug group, embodiment 1-3 group HA, LN content all significantly reduce (P<0.01 or P<0.05).
4.4 hepatic tissue pathology check results, in table 4.
Extent of liver fibrosis (n=12) respectively organized by table 4.
Table 4 result shows, and blank group rat does not find hepatic fibrosis; Model control group rat liver fibrosis degree is obvious, and 1 is 4 grades, and 7 is 5 grades, and 4 is 6 grades; Treatment group compares with model control group, and degree of hepatic fibrosis, liver tissues inflammatory cellular infiltration and steatosis degree alleviate all to some extent.Positive drug group 2 is only 1 grade, and 6 is 2 grades, and 4 is 3 grades; Embodiment is only 2 grades for 1 group 3, and 6 is 3 grades, and 3 is 4 grades; Embodiment is only 1 grade for 2 group 1, and 6 is 2 grades, and 4 is 3 grades, and 1 is 4 grades; Embodiment is only 1 grade for 3 group 1, and 7 is 2 grades, and 4 is 3 grades.Embodiment 1,2,3 groups of hepatic fibrosis average ranks are 3.00,2.42 and 2.25, reduction obvious with model control group 5.25, significant difference (P<0.05).
5. discuss
When there is hepatic fibrosis pathological changes, hepatocyte is damaged death, and ALT, AST etc. of its synthesis secretion are just transferred to blood through liver plasma membrane, and the content in blood is obviously raised; In addition, liver cell destruction is dead, and the albumin causing it to synthesize reduces.Therefore, ALT, AST, albumin serum levels can reflect hepatocyte injury degree.And LN level can reflect the Random early Detection of liver and the active process of liver tissue lesions, to the indication generation of hepatic fibrosis and the early diagnosis of liver cirrhosis, there is important value.During hepar damnification, in liver, Interstitial cell synthesis HA increases, and sinusoidal endothelial cell is impaired, and quantity reduces, and HA is decomposed and reduces, thus serum HA content is increased.This experimental result shows, Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones significantly can reduce ALT, AST (P<0.01 or P<0.05) of hepatic fibrosis rats, the albumin (P<0.01 or P<0.05) of remarkable rising hepatic fibrosis rats, significantly reduces LN, HA (P<0.01 or P<0.05) of hepatic fibrosis rats.In addition; show according to pathological examination results; Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones can obviously improve rat liver fibrosis degree; alleviate liver tissues inflammatory cellular infiltration and steatosis degree; show that Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones have Anti Fibrosis of Liver; the effect of protection hepatocyte, is improved effect to liver function.
Overall experiment effect display, Radix seu Caulis Embeliae Parviflorae extract and Radix seu Caulis Embeliae Parviflorae total flavones effectively can treat hepatic fibrosis, and therapeutic effect optimum is Radix seu Caulis Embeliae Parviflorae total flavones, and Radix seu Caulis Embeliae Parviflorae extract takes second place, but both all demonstrate significant therapeutic effect.
Although above with general explanation, detailed description of the invention and test, the present invention is described in detail, and on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (8)
1. the novelty teabag of Radix seu Caulis Embeliae Parviflorae in preparation treatment hepatic fibrosis medicines.
2. the novelty teabag of Radix seu Caulis Embeliae Parviflorae extract in preparation treatment hepatic fibrosis medicines.
3. purposes according to claim 2, it is characterized in that described Radix seu Caulis Embeliae Parviflorae extract is prepared by following steps and obtains: Radix seu Caulis Embeliae Parviflorae is pulverized, adding concentration is that the 50-70 DEG C of water-bath of 60-80% ethanol is extracted 2-3 time, and each ethanol consumption is medical material gross weight 8-12 times, and each extraction time is 40-60min, merge extractive liquid, concentrated, filter, concentrated, drying, obtains Radix Angelicae Sinensis rattan extract.
4. the novelty teabag of Radix seu Caulis Embeliae Parviflorae total flavones in preparation treatment hepatic fibrosis medicines.
5. purposes according to claim 4, it is characterized in that described Radix seu Caulis Embeliae Parviflorae total flavones is prepared by following steps and obtains: Radix seu Caulis Embeliae Parviflorae is pulverized, and adding concentration is 50-80% ethanol microwave extraction 2-3 time, each ethanol consumption is medical material gross weight 8-15 times, each extraction time is 10-20min, merge extractive liquid, concentrated, filter, after filtrate crosses weak-acid cation-exchange resin absorption, be 60-80% ethanol elution by concentration, eluent be concentrated, vacuum drying, obtain Radix seu Caulis Embeliae Parviflorae total flavones.
6. purposes according to claim 4, is characterised in that described Radix seu Caulis Embeliae Parviflorae total flavones is prepared by following steps and obtains: Radix seu Caulis Embeliae Parviflorae is pulverized, and adding concentration is 60% ethanol, by 780W microwave extraction 2-3 time, each ethanol consumption is medical material gross weight 12 times, and each extraction time is 15min, merge extractive liquid, concentrating under reduced pressure, add diatomite filtration, filtrate crosses ADS17 resin absorption, uses 70% ethanol elution, eluent is concentrated, vacuum drying, obtains Radix seu Caulis Embeliae Parviflorae total flavones.
7. Radix seu Caulis Embeliae Parviflorae extract becomes with pharmaceutically acceptable carrier combination preparing the novelty teabag for the treatment of in hepatic fibrosis medicines.
8. Radix seu Caulis Embeliae Parviflorae total flavones becomes with pharmaceutically acceptable carrier combination preparing the novelty teabag for the treatment of in hepatic fibrosis medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510297286.9A CN104857040A (en) | 2015-06-03 | 2015-06-03 | New purpose of embelia parviflora wall for preparing medicines for treating liver fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510297286.9A CN104857040A (en) | 2015-06-03 | 2015-06-03 | New purpose of embelia parviflora wall for preparing medicines for treating liver fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104857040A true CN104857040A (en) | 2015-08-26 |
Family
ID=53903507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510297286.9A Pending CN104857040A (en) | 2015-06-03 | 2015-06-03 | New purpose of embelia parviflora wall for preparing medicines for treating liver fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104857040A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105477474A (en) * | 2015-12-31 | 2016-04-13 | 广西梧州制药（集团）股份有限公司 | New application of rhizoma boldii in preparation of medicine for treating hepatic fibrosis |
| CN108610397A (en) * | 2018-05-04 | 2018-10-02 | 福州大学 | A kind of application of Radix Angelicae Sinensis albumen in preparing Protecting Hepatic Injury drug |
| CN110833556A (en) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | Use of pyrazolopyrimidine derivatives for the treatment of hepatic fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002011745A1 (en) * | 2000-08-04 | 2002-02-14 | Angiolab, Inc. | Composition containing ginkgo biloba that inhibit angiogenesis and matrix metalloproteinase |
| CN103768392A (en) * | 2014-01-09 | 2014-05-07 | 汤伟杰 | Traditional Chinese medicinal herb preparation for treating bone fracture and preparation method thereof |
-
2015
- 2015-06-03 CN CN201510297286.9A patent/CN104857040A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002011745A1 (en) * | 2000-08-04 | 2002-02-14 | Angiolab, Inc. | Composition containing ginkgo biloba that inhibit angiogenesis and matrix metalloproteinase |
| CN103768392A (en) * | 2014-01-09 | 2014-05-07 | 汤伟杰 | Traditional Chinese medicinal herb preparation for treating bone fracture and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨端云等: "当归藤中总黄酮提取工艺研究", 《食品卫生科技》 * |
| 高天宁等: "中药黄酮类成分抗化学性肝纤维化的研究进展", 《安徽医药》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105477474A (en) * | 2015-12-31 | 2016-04-13 | 广西梧州制药（集团）股份有限公司 | New application of rhizoma boldii in preparation of medicine for treating hepatic fibrosis |
| CN108610397A (en) * | 2018-05-04 | 2018-10-02 | 福州大学 | A kind of application of Radix Angelicae Sinensis albumen in preparing Protecting Hepatic Injury drug |
| CN108610397B (en) * | 2018-05-04 | 2020-11-10 | 福州大学 | Application of angelica sinensis protein in preparation of liver injury prevention medicine |
| CN110833556A (en) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | Use of pyrazolopyrimidine derivatives for the treatment of hepatic fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101862351B (en) | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine | |
| Wang et al. | Ethnopharmacological use, pharmacology, toxicology, phytochemistry, and progress in Chinese crude drug processing of the lateral root of Aconitum carmichaelii Debeaux.(Fuzi): a review | |
| CN106474145B (en) | Application of the Polysaccharides from Leaves of Moringa oleifera in preparation prevention and treatment alcoholic liver injury drug and food | |
| CN107375474B (en) | Vitiligo vitamine compound and preparation method thereof | |
| CN104857040A (en) | New purpose of embelia parviflora wall for preparing medicines for treating liver fibrosis | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN103585192B (en) | A kind of preparation method of Aleuritopteris argentea (Gmel.) Fee extract and application thereof | |
| CN102579519A (en) | Extracts of total saponins of pterocephalus hookeri and preparation method and application thereof | |
| CN103494860A (en) | Method for preparing lithospermum extract and application of lithospermum extract | |
| CN103690768B (en) | Join stilbene soft capsule and preparation method thereof the tuber of dwarf lilyturf | |
| CN102462710A (en) | Application of sunset abelmoschus flower total flavone to preparation of medicament for preventing and treating hepatofibrosis | |
| CN106491719A (en) | A kind of extracting method of leaf of Broussonetia papyrifera (L.) L.Her.ex Vent. total phenolic acid extract and its application | |
| CN103830288B (en) | Match certain herbaceous plants with big flowers extractive of general flavone and its production and use | |
| CN105287474A (en) | Application of p-hydroxyphenethylanisate | |
| Xin et al. | Antidepressant effect of water extract of royal sun medicinal mushroom, Agaricus brasiliensis (agaricomycetes), in mice exposed to chronic unpredictable mild stress | |
| CN104083690B (en) | Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing breast cancer | |
| CN100486600C (en) | Application of spanishneedles herb flavonid in preparing medicine for preventing and treating liver fibrosis | |
| CN101904953B (en) | Medicinal composition for diminishing inflammation and relieving pain and preparation method and use thereof | |
| CN103142695A (en) | Pharmaceutical composition for prevention and treatment of chronic glomerular diseases and preparation method of pharmaceutical composition | |
| CN109662970B (en) | A kind of application of lanostane-type | |
| CN103446220B (en) | Herba Artemisiae Annuae Radix Tripterygii Wilfordii medicine is to composition of medicine, preparation method and application | |
| CN101897766B (en) | Anti-inflammatory and analgesic medicine composition as well as preparation method and application thereof | |
| CN105213364A (en) | The application of khellactone | |
| CN105935439B (en) | Traditional Chinese medicine with effects of warming lung and descending turbidity and preparation method and application thereof | |
| CN105726624A (en) | Pharmaceutical composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150826 |